Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-TKI-resistant Non-Small Cell Lung Cancer”

54 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 54 results

Testing effectiveness (Phase 2)Looking for participantsNCT06071013
What this trial is testing

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Who this might be right for
Non-small Cell Lung CancerEGFR Gene MutationEGFR-TKI Resistant Mutation
China Medical University Hospital 20
Not applicableEnded earlyNCT02405247
What this trial is testing

TAURAS - T790 AURA ScreenFailure SOC Registry Study

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 400
Not applicableStudy completedNCT02575560
What this trial is testing

Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
EGFR-TKI Resistant Mutation
Qingdao Central Hospital 30
Large-scale testing (Phase 3)UnknownNCT03924050
What this trial is testing

Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

Who this might be right for
Non-small Cell Lung Cancer
Shanghai Junshi Bioscience Co., Ltd. 440
Testing effectiveness (Phase 2)UnknownNCT02098954
What this trial is testing

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

Who this might be right for
Carcinoma, Non-Small Cell LungEGFR Gene Mutation
Hunan Province Tumor Hospital 40
Not applicableWithdrawnNCT02368990
What this trial is testing

T790M Mutation Positive 2nd Line STandard of cAre Registry

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca
Testing effectiveness (Phase 2)UnknownNCT03123484
What this trial is testing

Β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

Who this might be right for
Non Small Cell Lung Cancer
China Medical University, China 80
Very early researchNot Yet RecruitingNCT07498595
What this trial is testing

TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC

Who this might be right for
EGFR-TKI-resistant Non-Small Cell Lung Cancer
Tianjin Medical University General Hospital 50
Not applicableUnknownNCT02988141
What this trial is testing

EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC

Who this might be right for
Nonsmall Cell Lung Cancer
Jianxing He 100
Testing effectiveness (Phase 2)UnknownNCT04405674
What this trial is testing

Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Shanghai Chest Hospital 120
Not applicableUnknownNCT01776684
What this trial is testing

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

Who this might be right for
EGFR Mutation Positive Non-small Cell Lung Cancer
Samsung Medical Center 200
Early research (Phase 1)UnknownNCT03050411
What this trial is testing

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Who this might be right for
Nonsmall Cell Lung Cancer
Peking University Third Hospital 30
Early research (Phase 1)UnknownNCT02066870
What this trial is testing

Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI

Who this might be right for
Non-small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 9
Testing effectiveness (Phase 2)Ended earlyNCT02495233
What this trial is testing

ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Who this might be right for
Non-Small-Cell Lung Cancer
Astellas Pharma Global Development, Inc. 10
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06634667
What this trial is testing

Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance

Who this might be right for
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital 30
Large-scale testing (Phase 3)Study completedNCT03515837
What this trial is testing

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 492
Testing effectiveness (Phase 2)UnknownNCT06277674
What this trial is testing

Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI

Who this might be right for
Non-small Cell Lung Cancer
Guangzhou University of Traditional Chinese Medicine 20
Testing effectiveness (Phase 2)Ended earlyNCT04971187
What this trial is testing

Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer

Who this might be right for
Locally Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8+7 more
M.D. Anderson Cancer Center 3
Not applicableUnknownNCT04007835
What this trial is testing

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Who this might be right for
NSCLC
Guangdong Association of Clinical Trials 120
Not applicableUnknownNCT03532698
What this trial is testing

Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IVEGFR T790M
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 100
Load More Results